OCUGEN INC. - COMMON STOCK
0.7800
24-1月-25 16:45:00
15 分の遅延
株式
9.9999999999989E-05
+0.01%
本日の幅
0.7701 - 0.8199
ISIN
N/A
ソース
NASDAQ
-
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
12 8 2022 07:30:22 提供 Nasdaq GlobeNewswire
-
Ocugen Provides Business Update & Second Quarter 2022 Financial Results
05 8 2022 07:30:26 提供 Nasdaq GlobeNewswire
-
29 7 2022 07:30:58 提供 Nasdaq GlobeNewswire
-
21 6 2022 07:00:00 提供 Nasdaq GlobeNewswire
-
Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
14 6 2022 07:00:00 提供 Nasdaq GlobeNewswire
-
13 6 2022 07:00:00 提供 Nasdaq GlobeNewswire
-
Ocugen, Inc. to Present at BIO International Convention 2022
09 6 2022 18:17:10 提供 Nasdaq GlobeNewswire
-
24 5 2022 07:11:00 提供 Nasdaq GlobeNewswire
-
Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
23 5 2022 07:34:00 提供 Nasdaq GlobeNewswire
-
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)
23 5 2022 06:36:00 提供 Nasdaq GlobeNewswire
-
Ocugen Provides Business Update and First Quarter 2022 Financial Results
06 5 2022 06:33:00 提供 Nasdaq GlobeNewswire
-
02 5 2022 07:37:00 提供 Nasdaq GlobeNewswire
-
29 4 2022 11:36:00 提供 Nasdaq GlobeNewswire
-
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
25 4 2022 07:33:00 提供 Nasdaq GlobeNewswire
-
Ocugen, Inc. to Present at NobleCon18
19 4 2022 17:32:00 提供 Nasdaq GlobeNewswire
-
Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
18 4 2022 07:11:00 提供 Nasdaq GlobeNewswire
-
Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)
12 4 2022 08:31:00 提供 Nasdaq GlobeNewswire
-
01 4 2022 07:37:00 提供 Nasdaq GlobeNewswire
-
Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
23 3 2022 07:44:00 提供 Nasdaq GlobeNewswire
-
21 3 2022 18:36:00 提供 Nasdaq GlobeNewswire